NASDAQ · Drug Manufacturers - Specialty & Generic

Pacira BioSciences, Inc. (PCRX) Stock

$36.32 -0.21% NASDAQ: PCRX Healthcare

Valuation

MetricValue
Price$36.32
Market Cap$1.43B
P/E Ratio71.14
P/B Ratio1.47
P/S Ratio1.32
EPS (TTM)$0.13
52-Week High$36.39
52-Week Low$18.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE2.13%
ROA1.18%
ROCE1.64%
Gross Margin4.55%
Operating Margin4.55%
Net Margin1.96%
Debt/Equity0.61
Current Ratio4.53

Annual Financials (USD)

Metric20212022202320242025
Revenue$542.0M$667.0M$675.0M$701.0M$726.0M
Operating Profit$90.0M$60.0M$88.0M$-73.0M$33.0M
Net Profit$42.0M$16.0M$42.0M$-100.0M$7.0M
EPS$0.92$0.34$0.89$-2.15$0.16
Op Margin16.6%9.0%13.0%-10.5%4.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.1B$1.7B$1.6B$1.6B$1.3B
Total Liabilities$1.3B$906.0M$704.0M$775.0M$572.0M
Cash$586.0M$104.0M$153.0M$277.0M$159.0M
Borrowings$1.1B$763.0M$586.0M$639.0M$454.0M

Latest News

PCRX: Lowering target price to $26.00 Argus Research · Jul 15, 2026 Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 8, 2026 PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare Zacks · Jul 2, 2026 Zimmer Biomet (ZBH) Is Buying Pacira’s Iovera Device And Expanding Into Spasticity Simply Wall St. · Jul 2, 2026 Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday MT Newswires · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$126.0M$145.0M$155.0M$189.0M$152.0M
Investing Cash Flow$-67.0M$-255.0M$62.0M$-94.0M$84.0M
Financing Cash Flow$-10.0M$-1.0M$-2.0M$-59.0M$-154.0M
Net Cash Flow$486.0M$-481.0M$49.0M$123.0M$-118.0M
Free Cash Flow$80.0M$115.0M$139.0M$179.0M$137.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.10
EV / EBITDA10.38
FCF Yield18.22%
Quick Ratio3.94
Interest Coverage1.33
Return 1Y16.54%
Return 3Y-29.63%
Return 5Y-55.40%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.15 -1.25% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $534.86 +2.34% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.71 +0.98% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $260.90 +2.69% 19.82 $2.81T 0.00%
METAMeta Platforms, Inc. $719.12 -0.25% 27.93 $1.83T 0.28%

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. is led by CEO Frank D. Lee, employs 788 people, headquartered in US, publicly traded since 2011.

Pacira BioSciences, Inc. (PCRX) stock trades at $36.32 with a market capitalization of $1.43B. The stock is valued at a price-to-earnings (P/E) ratio of 71.14, price-to-book of 1.47, price-to-sales of 1.32. Over the past 52 weeks the stock has ranged between $18.80 and $36.39, and currently trades at its 52-week high.

On profitability, Pacira BioSciences, Inc. generates a return on equity (ROE) of 2.13%, return on capital employed of 1.64%, an operating margin of 4.55%, a net profit margin of 1.96%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1175.58 +0.51% JNJ Johnson & Johnson $260.45 +1.55% ABBV AbbVie Inc. $276.42 +1.47% MRK Merck & Company, Inc. Common Stock (new) $146.15 +2.64% UNH UnitedHealth Group Incorporated Common Stock (DE) $380.92 +2.69% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $660.31 +1.28% AMGN Amgen Inc. $416.42 +2.20% GILD Gilead Sciences, Inc. $150.86 +2.56% ABT Abbott Laboratories $99.23 +0.75% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides